Begin main content

Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness

Last updated: May 15, 2019
Project Number: RC1119-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical effectiveness of ivabradine for patients with stable chronic heart failure and with left ventricular ejection fraction > 35% and 40%?

Key Message

There were no studies identified with inclusion criteria of patients with stable chronic heart failure and left ventricular ejection fraction greater than 35% and less than or equal to 40% Two studies, however, included patients with LVEF less than 40% and were included because the mean LVEF was greater than 35% and less than or equal to 40%. One study was a randomized controlled trial comparing ivabradine plus carvedilol to carvedilol. The second study was a non-randomized study, also comparing ivabradine plus carvedilol to carvedilol. Patients in the ivabradine groups demonstrated improvement in numerous outcomes, including resting and mean heart rate reduction, New York Heart Association classification, quality of life outcomes, and left ventricular ejection fraction.